Bayer Pharmaceuticals announced this week that its cancer drug, Copanlisib, has been granted priority review by the FDA. The expedited process means that Bayer will know within 6 months whether Copanlisib has been granted regulatory approval versus the standard 10 month approval period. In its phase 2 clinical study, Bayer concluded that the Objective Response Rate in 142 patients was 59.2% while the Complete Response Rate was 12%. Read the full press release here.